IL6 and episodic ataxia type 2: Moreover, anti-interleukin-6 (IL-6) receptor treatment, such as tocilizumab therapy that is widely used to treat COVID-19, seems to potentially confer higher risk for developing CAPA as the significantly elevated level of IL-6 in severe COVID-19 patients has also been found as a contributing factor in protection against Aspergillus (Table 1; Guaraldi et al., 2020; Bartoletti et al., 2021; Feys et al., 2021).